289.92MMarket Cap-2381P/E (TTM)
5.380High5.040Low91.84KVolume5.160Open5.040Pre Close480.95KTurnover0.30%Turnover RatioLossP/E (Static)55.33MShares9.97052wk High-2.97P/B163.29MFloat Cap2.70052wk Low--Dividend TTM31.16MShs Float28.265Historical High--Div YieldTTM6.75%Amplitude2.700Historical Low5.236Avg Price1Lot Size
Foghorn Therapeutics Stock Forum
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet